Seattle-based biotech startup Talus Bioscience landed $4.3 million in non-dilutive grants to boost development of its drug discovery platform that seeks compounds that affect gene activity. The startup received $2.3 million from Spokane, Wash.-based Andy Hill Cancer Research Endowment (CARE) Fund. It received an additional $2 million from small business innovation research (SBIR), a U.S. government-funded program. Talus is led by CEO Alex Federation, a biochemist and computational biologist, and CTO Lindsay Pino, who has a background in biochemistry and machine learning.
